ESSA Pharma Inc. Amends Agreement with XenoTherapeutics

Accessibility StatementSkip Navigation Shareholders expected to receive approximately $0.12 per share in cash upon closing of transaction and up to approximately $0.14 per CVR under revised terms Further Adjourns Special Meeting to October 3, 2025 SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, Sept. 24, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that it has reached an agreement to amend its previously announced Business Combination Agreement (the "Amended ...